Liu, J., O’Malley, D., Nieuwenhuysen, E. V., Moore, K., Hamilton, E., Yeku, O., Bouberhan, S., Hou, J., Schröder, D., Wang, B., Yoo, S.-Y., Govindraj, S., Brouwer-Visser, J., Peterman, M., Schmidt, T., Barnes, B., Lowy, I., Uldrick, T., Miller, E., & O’Cearbhaill, R. (2023). PO011LBA/#1512  Ubamatamab (MUC16XCD3 bispecific antibody) with or without cemiplimab (Anti-PD-1 antibody) in recurrent ovarian cancer: phase 1 clinical and biomarker results. Plenary 03: Oral Abstract Presentations – Ovarian Cancer. https://doi.org/10.1136/ijgc-2023-igcs.11